BNP Paribas Asset Management
BPMC

BNP Paribas Asset Management’s Blueprint Medicines BPMC Stock Holding History

BNP Paribas Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-584
Closed -$75K – 1893
2025
Q2 		$75K Sell
584
-69,303
-99% -$7.2M ﹤0.01% 1002
2025
Q1 		$6.18M Hold
69,887
– – 0.02% 514
2024
Q4 		$6.1M Hold
69,887
– – 0.02% 520
2024
Q3 		$6.46M Buy
+69,887
New +$6.94M 0.02% 501

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

BNP Paribas Asset Management's BPMC Position: Q3 2025 in Review

BNP Paribas Asset Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 584 shares — an estimated $75K sold.

BNP Paribas Asset Management first reported a position in BPMC in Q3 2024 and held it in 4 quarters. The position peaked at $6.46M in Q3 2024. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • BNP Paribas Asset Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • BNP Paribas Asset Management sold 584 Blueprint Medicines shares in Q3 2025, an estimated $75K.
  • BNP Paribas Asset Management first reported a position in Blueprint Medicines in Q3 2024 and held it in 4 quarters.
  • BNP Paribas Asset Management's Blueprint Medicines position peaked at $6.46M in Q3 2024.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on BNP Paribas Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.